Income Statement
OVID THERAPEUTICS INC.
OVID
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY |
|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
230.70 | 223.50 | 0.39 | 1.50 | - | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - |
|
Gross Profit
|
230.70 | 223.50 | 0.39 | 1.50 | - | - | - | - | - |
|
Operating Expenses
|
49.69 | 62.45 | 59.67 | 57.05 | 84.17 | 94.05 | 61.41 | 52.93 | 65.01 |
|
Research & Development
|
25.58 | 36.77 | 28.59 | 24.62 | 46.94 | 63.42 | 42.16 | 33.79 | 49.97 |
|
Selling, General & Administrative
|
24.11 | 25.68 | 31.09 | 32.43 | 37.23 | 30.63 | 19.25 | 19.14 | 15.04 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - |
|
Operating Income
|
181.01 | 161.05 | -59.28 | -55.55 | -84.17 | -94.05 | -61.41 | -52.93 | -65.01 |
|
Non-Operating Income
|
198.42 | 187.48 | -6.94 | -1.38 | -208.34 | - | 0.95 | 0.95 | 0.20 |
|
Interest Income
|
2.03 | 3.92 | - | - | - | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
25.03 | 35.45 | 6.94 | 1.38 | - | - | - | - | - |
|
Income Before Tax
|
-17.41 | -26.43 | -52.34 | -54.17 | 124.16 | - | - | - | - |
|
Income Tax Expense
|
0.00 | 0.00 | 0.00 | 0.00 | 1.33 | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - |
|
Net Income
|
-17.41 | -26.43 | -52.34 | -54.17 | 122.83 | -81.04 | -60.46 | -51.98 | -64.81 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY |
|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - |
|
EBITDA
|
181.28 | 161.66 | -58.71 | -55.04 | -83.94 | -93.74 | -61.15 | -52.79 | -64.93 |
|
Earnings Per Share (Basic)
|
-0.23 | -0.37 | -0.74 | -0.77 | 1.78 | - | - | - | - |
|
Diluted EPS
|
-0.23 | -0.37 | -0.74 | -0.77 | 1.76 | - | - | - | - |
|
Weighted Average Shares
|
73.74 | 70.91 | 70.58 | 70.42 | 67.48 | - | - | - | - |
|
Diluted Weighted Avg Shares
|
73.74 | 70.91 | 70.58 | 70.42 | 68.07 | - | - | - | - |
|
Comprehensive Income
|
-17.58 | -26.47 | -52.34 | -54.21 | 122.83 | -81.04 | -60.46 | -51.98 | - |